BioNTech and Pfizer Present Bispecific Antibody Data at Oncology Meeting

BioNTech and Pfizer presented clinical data on bispecific antibodies during the second day of the American Society of Clinical Oncology annual meeting on May 30, 2026. The companies reported results from studies examining the therapies in lung cancer and other tumor types. The presentations formed part of broader updates on new immunotherapies discussed at the meeting.

An FDA official stated that competition from China and changes at the agency create an opportunity for restructuring. The comments were made in the context of ongoing drug development discussions at the meeting. The official described the current period as one that could allow the agency to adjust its operations.

No specific timeline or policy changes were outlined in the remarks. Data from additional companies on multiple myeloma treatments were also presented during the same session.